Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

“I think the results are very encouraging, and I hope that industry will take it on and do a regulatory approval trial for semaglutide in type 1,” he added. The 26-week ADJUST-T1D randomized clinical ...

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Researchers have found in phase IIIa REDEFINE 1 trial that Addition of investigational cagrilintide to GLP-1 agonist ...

In this 26-week, double-blind trial of 72 adults, 36% who received 1 mg of the GLP-1 receptor agonist weekly achieved the trial's primary composite outcome by week 26 compared with no patients in ...